Ascendis Pharma Endocrinology Division A/s

Ascendis Pharma Growth Disorders Division A/s

Susanne Kindermann

Harald Rau

Thomas Wegge

Grethe Nørskov Rasmussen

Ulrich Hersel

Grethe Norskov Rasmussen

Kennett Sprogøe

Torben Lessmann

Torben Leßmann

Kennett Sprogoe

Torben Lebmann

Grethe Noerskov Rasmussen

A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.

PEGylated recombinant human growth hormone compounds

The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.

Dry growth hormone composition transiently linked to a polymer carrier

The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8&#xb0; C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts.

PEGylated Recombinant Human Growth Hormone Compounds

Growing community of inventors

Liestal, Switzerland

Susanne Kindermann